动态增强与扩散加权MRI早期预测乳腺癌新辅助化疗病理完全缓解的列线图
研究纳入87例乳腺癌患者,在2周期新辅助化疗前后行MRI检查,按3:1随机分为训练集和验证集。多因素分析显示2周期后ADC值、E90下降百分比和肿瘤大小下降百分比为pCR的独立预测因素,预测模型在训练集和验证集的AUC分别为0.939和0.944,基于模型构建的列线图对pCR具有较强预测价值。
要点
- 2周期新辅助化疗后ADC值、E90下降百分比和肿瘤大小下降百分比为pCR独立预测因素。
- 预测模型在训练集AUC为0.939、验证集AUC为0.944,列线图对pCR有较强预测价值。
- 联合动态增强MRI与扩散加权成像可早期预测乳腺癌新辅助化疗后的pCR。
核心结论
- 联合动态增强MRI与扩散加权成像可准确预测2周期新辅助化疗后的pCR,预测模型和列线图对pCR具有较强预测价值。
研究设计与样本
- 研究纳入87例乳腺癌患者,在2周期新辅助化疗前后行MRI检查,按3:1随机分为训练集和验证集。
- 测量MRI参数包括肿瘤最长径、时间-信号强度曲线、早期强化率(E90)、最大强化率和ADC值,并计算各参数的百分比变化。
- 训练集采用单因素分析和多因素logistic回归分析评估pCR的独立预测因素,验证集用于测试预测模型,并基于预测模型构建列线图。
诊断标准与关键数值
- 2周期新辅助化疗后ADC值为pCR的独立预测因素,OR=1.041,95%CI(1.002,1.081),p=0.037。
- E90下降百分比为pCR的独立预测因素,OR=0.927,95%CI(0.881,0.977),p=0.004。
- 肿瘤大小下降百分比为pCR的独立预测因素,OR=0.948,95%CI(0.909,0.988),p=0.011。
- 预测模型在训练集AUC为0.939,在验证集AUC为0.944。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: The study investigated the potential of the combined use of dynamic contrast-enhanced MRI and diffusion-weighted imaging in predicting the pathological complete response (pCR) of neoadjuvant chemotherapy (NAC) after two cycles of NAC.
MATERIALS AND METHODS: Eighty-seven patients with breast cancer who underwent MR examination before and after two cycles of NAC were enrolled. The patients were randomly assigned to a training cohort and a validation cohort (3:1 ratio). MRI parameters including tumor longest diameter, time-signal intensity curve, early enhanced ratio (E90), maximal enhanced ratio and ADC value were measured, and percentage change in MRI parameters were calculated. Univariate analysis and multivariate logistic regression analysis were used to evaluate independent predictors of pCR in the training cohort. The validation cohort was used to test the prediction model, and the nomogram was created based on the prediction model.
RESULTS: This study demonstrated that the ADC value after two cycles of NAC (OR = 1.041, 95% CI (1.002, 1.081); p = 0.037), percentage decrease in E90 (OR = 0.927, 95% CI (0.881, 0.977); p =0.004) and percentage decrease in tumor size (OR = 0.948, 95% CI (0.909, 0.988); p = 0.011) were significantly important for independently predicting pCR. The prediction model yielded AUC of 0.939 and 0.944 in the training cohort and the validation cohort, respectively.
CONCLUSION: The combined use of dynamic contrast-enhanced MRI and diffusion-weighted imaging could accurately predict pCR after two cycles of NAC. The prediction model and the nomogram had strong predictive value to NAC.
引用
- Zhao R, Lu H, Li YB, et al. Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Dynamic Contrast-enhanced and Diffusion-weighted MRI. Acad Radiol. 2021. PMID: 33593702. doi:10.1016/j.acra.2021.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。